Answers are grounded in this paper and cite their sources.
In 4 patients with subarachnoid haemorrhage after ruptured intracranial aneurysm, tranexamic acid (AMCA) was used to prevent the recurrence of the bleeding. 1000 mg of AMCA was given intravenously 6 times a day for 8 days. The fibrinolytic activity of blood and spinal fluid was measured simultaneously with the etermination of AMCA levels before and after the beginning of treatment. The fibrin plate method showed no fibrinolytic activity in plasma or in CSF. Local fibriolysis was demonstrated by the presence of fibrin degradation products in spinal fluid. After repeated administration, AMCA crossed the blood-brain barrier and effectively inhibited the local fibrinolysis within the spinal fluid. The findings in this study suggest that in patients with subarachnoid haemorrhage AMCA should be aministrated intravenously in a dosage of 15–20 mg/kg body weight 6 times a day as soon as possible after the bleeding. But treatment with the antifibrinolytic drug does not change the indication for surgical therapy.
No takes yet. Share an insight, caveat, or question.
Tovi et al. (1972) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: